Unresolved compliance issues at a manufacturing plant operated by Novo Nordisk have led to a complete response letter for Scholar Rock's lead drug for spinal muscular atrophy (SMA). The CRL is related ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback